Is Flora Growth Corp. overvalued or undervalued?

As of 9 August 2022, Flora Growth Corp. has moved from a grade of "does not qualify" to "risky." The company appears to be overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.04, an EV to Sales ratio of 0.30, and a troubling ROCE of -218.48%.
In comparison to its peers, Flora Growth Corp. has a significantly negative EV to EBITDA ratio of -1.25, while Upexi, Inc. shows a worse EV to EBITDA of -37.9754, and ProPhase Labs, Inc. has a less negative EV to EBITDA of -1.6442. Despite a recent positive stock return of 10.27% over the past month compared to the S&P 500's 2.33%, the year-to-date return of -35.85% against the S&P's 12.22% indicates ongoing struggles for the company.